BRCA1 and ovarian cancer: The B,D-dilactam steroidal alkylator ASA-B presented a more clear synthetic lethality attribute in BRCA-1 mutated UWB1.289 ovarian cancer cells due to its corresponding cytostatic and cytotoxic effects in relation to its inhibitory activity on PARP enzymes.